INC. (NASDAQ:INCR) Files An 8-K Other Events
Item 8.01.
On July 13, 2020, ThermoGenesis Holdings, Inc. (the “Company”), entered into a Manufacturing and Supply Amending Agreement #2 with CBR Systems, Inc. (“CBR”) with an effective date of July 13, 2020 (the “Amendment”). The Amendment modifies the Manufacturing and Supply Agreement entered into on May 15, 2017 and the first amendment dated March 16, 2020 by the Company and CBR (the “Original Agreement”). The Amendment, among other things, amends the Original Agreement to revise the amount of certain products to be purchased, pricing of those products and removal of the safety stock requirement.
In addition, the Amendment replaces Section 5(b)(i) of the Sixth Amended and Restated Technology License and Escrow Agreement included as Exhibit F of the Original Agreement by updating the financial requirement to exclude convertible debt from the definition of short-term debt. The new language in Section 5(b)(i) under events or conditions that constitute a default states that “Thermo’s cash balance and short-term investments net of non-convertible debt and borrowed funds that are payable with one (1) year is less than One Million Dollars ($1,000,000) at any month end unless Thermo cures such default within thirty (30) days of the end of such month”.
The foregoing description of the Amendment is incomplete and is qualified by reference to the full text of the Amendment, which is attached as Exhibit 10.1 hereto and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
*Information contained in portions of this Exhibit has been redacted because the Company has determined that such information (i) is not material and (ii) would likely cause competitive harm to the Company if it were to be publicly disclosed. Information redacted from this Exhibit has been marked by the following [**].
ThermoGenesis Holdings, Inc. Exhibit
EX-10.1 2 ex_194290.htm EXHIBIT 10.1 ex_194290.htm Exhibit 10.1 **Information contained in portions of this Exhibit has been redacted because the Company has determined that such information (i) is not material and (ii) would likely cause competitive harm to the Company if it were to be publicly disclosed. Information redacted from this Exhibit has been marked by the following [**]. MANUFACTURING AND SUPPLY AMENDING AGREEMENT #2 This AMENDING AGREEMENT #2 (“Amendment #2”) is effective as of July 13,…
To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
